LitAlert ~~ GeneLit.com

Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Perez-Fidalgo JA, Guerra E, García Y, Iglesias M, Hernández-Sosa M, Estevez-García P, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A.
Int J Gynecol Cancer. 2023 Feb 9:ijgc-2022-004028. doi: 10.1136/ijgc-2022-004028. Epub ahead of print.

Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
Musacchio L, Boccia S, Marchetti C, Minucci A, Camarda F, Cassani C, Ventriglia J, Salutari V, Ghizzoni V, Giudice E, Perri MT, Carbone MV, Ricci C, Pignata S, Fagotti A, Scambia G, Lorusso D.
Int J Gynecol Cancer. 2023 Feb 9:ijgc-2022-003903. doi: 10.1136/ijgc-2022-003903. Epub ahead of print.

Contralateral lymph node metastasis in recurrent ipsilateral breast cancer with Lynch syndrome: a locoregional event.
Zwimpfer TA, Schwab FD, Steffens D, Kaul F, Schmidt N, Geiger J, Geissler F, Heinzelmann-Schwarz V, Weber WP, Kurzeder C.
World J Surg Oncol. 2023 Feb 9;21(1):40. doi: 10.1186/s12957-023-02918-w.

Study on TFF1 and PALB2 gene variants associated with gastric carcinoma risk in the Chinese Han population.
Zou W, Zhang Q, Sun R, Li X, He S.
Cancer Epidemiol. 2023 Feb 7;83:102333. doi: 10.1016/j.canep.2023.102333. Epub ahead of print.

Atypical ATMs: Broadening the Phenotypic Spectrum of ATM-associated Hereditary Cancer.
Borja NA, Silva-Smith R, Huang M, Parekh DJ, Sussman D, Tekin M.
Front Oncol. 2023 Feb 3;13:1068110. doi: 10.3389/fonc.2023.1068110.